HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy

Ovarian cancer is the leading cause of gynecological cancer mortality, with no current screening method effective for early diagnosis, with 75% of advanced stage patients being detected. Not all patients are candidates for standard treatment, which is primary cytoreduction followed by adjuvant chemotherapy, due to the advanced process. A subgroup of patients will receive neoadjuvant chemotherapy followed by interval surgery, which allows higher rates of optimal cytoreduction with low morbidity and mortality. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a therapeutic option that is used in pathologies of peritoneal dissemination, whose morbidity and mortality has been reported in several series and is promising as a management option for ovarian cancer, so it is necessary to evaluate morbidity and mortality that conditions this modality of treatment as well as if it impacts on the quality of life of the patients to whom they are performed, which will allow offering our patients an option of additional treatment to the standard.

NCT Number	NCT03275194
Lead Sponsor	Instituto Nacional de Cancerologia de Mexico
Conditions	HPEC, Ovarian Cancer, Women's Health: Neoplasm of Ovary, Chemotherapy Effect
Enrollment	100 participants
Start Date	2017-09-02
Primary Completion	2025-12-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2023-04-28